中国
药物开发
药品
药物发现
传统医学
医学
中医药
风险分析(工程)
药理学
替代医学
政治学
生物信息学
生物
病理
法学
作者
Wanying Wu,Jinjun Hou,Huali Long,Wenzhi Yang,Jian Liang,De‐an Guo
标识
DOI:10.1016/s1875-5364(14)60050-9
摘要
Over the past 30 years, China has significantly improved the drug development environment by establishing a series of policies for the regulation of new drug approval. The regulatory system for new drug evaluation and registration in China was gradually developed in accordance with international standards. The approval and registration of TCM in China became as strict as those of chemical drugs and biological products. In this review, TCM-based new drug discovery and development are introduced according to the TCM classification of nine categories.
科研通智能强力驱动
Strongly Powered by AbleSci AI